SELLAS Life Sciences Group, Inc.
Price Action
Technical Summary
EMERGING TRENDSELLAS Life Sciences Group, Inc. shows underlying uptrend characteristics but has temporarily lost support at the 50-day moving average. Relative strength is leading (RS Rating: 93), indicating clear outperformance against the broad market. Earnings growth of 37% provides fundamental context to the price action. Investors should exercise caution due to high volatility (90% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $4.88 | +1.00% | ABOVE |
| 50 SMA | $4.96 | -0.50% | BELOW |
| 100 SMA | $4.32 | +14.01% | ABOVE |
| 150 SMA | $3.47 | +42.08% | ABOVE |
| 200 SMA | $3.03 | +62.51% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is SLS in an uptrend right now?
SLS has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is SLS overbought or oversold?
SLS's RSI (14) is 56. The stock is in neutral territory, neither overbought nor oversold.
Is SLS outperforming the market?
SLS has a Relative Strength (RS) Rating of 93 out of 99. Yes, SLS is a market leader, outperforming 93% of all stocks over the past 12 months.
Where is SLS in its 52-week range?
SLS is trading at $4.93, which is 80% of its 52-week high ($6.14) and 75% above its 52-week low ($1.36).
How volatile is SLS?
SLS has a Beta of 1.34 and 52-week volatility of 90%. It's more volatile than the S&P 500 - expect bigger swings.